Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2026)

Top pharmaceutical stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best pharmaceutical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

Bausch Health Companies (NYSE:BHC) is the #1 top pharmaceutical stock out of 74 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch Health Companies (NYSE:BHC) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: C.

Bausch Health Companies (NYSE:BHC) has a Due Diligence Score of 9, which is -20 points lower than the pharmaceutical industry average of 29. Although this number is below the industry average, our proven quant model rates BHC as a "A".

BHC passed 3 out of 33 due diligence checks and has weak fundamentals. Bausch Health Companies has seen its stock return 29.53% over the past year, overperforming other pharmaceutical stocks by 129 percentage points.

Bausch Health Companies has an average 1 year price target of $9.00, an upside of 8.56% from Bausch Health Companies's current stock price of $8.29.

Bausch Health Companies stock has a consensus Hold recommendation according to Wall Street analysts. Of the 2 analysts covering Bausch Health Companies, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Eton Pharmaceuticals (NASDAQ:ETON) is the #2 top pharmaceutical stock out of 74 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Eton Pharmaceuticals (NASDAQ:ETON) is: Value: B, Growth: B, Momentum: A, Sentiment: A, Safety: D, Financials: A, and AI: C.

Eton Pharmaceuticals (NASDAQ:ETON) has a Due Diligence Score of 67, which is 38 points higher than the pharmaceutical industry average of 29.

ETON passed 23 out of 33 due diligence checks and has strong fundamentals. Eton Pharmaceuticals has seen its stock return 299.17% over the past year, overperforming other pharmaceutical stocks by 399 percentage points.

Eton Pharmaceuticals has an average 1 year price target of $75.75, an upside of 12.16% from Eton Pharmaceuticals's current stock price of $67.54.

Eton Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Eton Pharmaceuticals, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amphastar Pharmaceuticals (NASDAQ:AMPH) is the #3 top pharmaceutical stock out of 74 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Amphastar Pharmaceuticals (NASDAQ:AMPH) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a Due Diligence Score of 48, which is 19 points higher than the pharmaceutical industry average of 29.

AMPH passed 15 out of 33 due diligence checks and has strong fundamentals. Amphastar Pharmaceuticals has seen its stock return 11.26% over the past year, overperforming other pharmaceutical stocks by 111 percentage points.

Amphastar Pharmaceuticals has an average 1 year price target of $22.00, a downside of -24.29% from Amphastar Pharmaceuticals's current stock price of $29.06.

Amphastar Pharmaceuticals stock has a consensus Hold recommendation according to Wall Street analysts. Of the 4 analysts covering Amphastar Pharmaceuticals, 0% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 25% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 9 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 28.3%, which is 21 percentage points higher than the pharmaceutical industry average of 7.61%.

Cumberland Pharmaceuticals's dividend payout ratio of -411% indicates that its high dividend yield might not be sustainable for the long-term.

Supernus (NASDAQ:SUPN) has an annual dividend yield of 28.28%, which is 21 percentage points higher than the pharmaceutical industry average of 7.61%.

Supernus's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Kamada (NASDAQ:KMDA) has an annual dividend yield of 5.18%, which is -2 percentage points lower than the pharmaceutical industry average of 7.61%.

Kamada's dividend payout ratio of 65.7% indicates that its high dividend yield is sustainable for the long-term.

Pharmaceutical stocks were up 1.21% in the last day, and up 3.12% over the last week. Harrow was the among the top gainers in the drug manufacturers - specialty & generic industry, gaining 10.52% yesterday.

Harrow shares are trading higher after the company reported better-than-expected Q3 financial results and affirmed its FY26 sales guidance above estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 64 points higher than the pharmaceutical industry average of 22. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 90.12% in the past year. It has overperformed other stocks in the pharmaceutical industry by 190 percentage points.

Phibro Animal Health (NASDAQ:PAHC) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Phibro Animal Health has a valuation score of 43, which is 21 points higher than the pharmaceutical industry average of 22. It passed 3 out of 7 valuation due diligence checks.

Phibro Animal Health's stock has dropped -24.42% in the past year. It has overperformed other stocks in the pharmaceutical industry by 76 percentage points.

Ani Pharmaceuticals (NASDAQ:ANIP) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ani Pharmaceuticals has a valuation score of 57, which is 35 points higher than the pharmaceutical industry average of 22. It passed 4 out of 7 valuation due diligence checks.

Ani Pharmaceuticals's stock has dropped -19.88% in the past year. It has overperformed other stocks in the pharmaceutical industry by 80 percentage points.

48.84% of pharmaceutical stocks rated by analysts are a strong buy right now. On average, analysts expect pharmaceutical stocks to rise by 171.32% over the next year.

10.87% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 21.74% of pharmaceutical stocks are rated B (Buy), 39.13% are rated C (Hold), 19.57% are rated D (Sell), and 8.7% are rated F (Strong Sell).